Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Caprice Greystoke

This article was originally published in The Tan Sheet

Executive Summary

Met with FDA on April 21 to discuss its appetite suppressant product Spray-U-Thin (phenylpropanolamine). The meeting was in response to a February warning letter from FDA that charged that Spray-U-Thin is a new drug not covered under the OTC weight control drug monograph "based on the dosage...and the method and duration of administration of the active ingredient." FDA also cited misleading labeling claims and several good manufacturing practices infractions in the letter. Caprice Greystoke said it is continuing to manufacture and market the product while it attempts to address FDA's concerns
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082741

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel